Treating the spectrum of type 2 diabetes: Emphasis on insulin pump therapy

Diabetes Educator

Volumn 32, Issue 1 SUPPL., 2006, Pages

  Wittlin, Steven D ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

AGED; CASE REPORT; CLASSIFICATION; DIABETIC DIET; DISEASE COURSE; ECONOMICS; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN INFUSION; INSULIN RESISTANCE; INSURANCE; MEDICARE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORGANIZATION AND MANAGEMENT; PANCREAS ISLET BETA CELL; PATIENT ATTITUDE; PATIENT EDUCATION; PATIENT SELECTION; PSYCHOLOGICAL ASPECT; REVIEW; TREATMENT OUTCOME; UNITED STATES; UTILIZATION REVIEW;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DISEASE PROGRESSION; EXERCISE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN INFUSION SYSTEMS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; INSURANCE COVERAGE; MEDICARE; OBESITY; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT EDUCATION; PATIENT SELECTION; TREATMENT OUTCOME; UNITED STATES;

EID: 32144451686     PISSN: 01457217     EISSN: 15546063     Source Type: Journal    
DOI: 10.1177/0145721705285642     Document Type: Review

References (27)

1. Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract. 2004;66:S37-S43.
2. UK Prospective Diabetes Study. UK Prospective Diabetes Study 16: overview of 6 years of therapy of type II diabetes-a progressive disease. Diabetes. 1995;44:1249-1258.
3. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial. Ann Intern Med. 1998;128:517-523.
4. UK Prospective Diabetes Study. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
5. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005;28:S4-36S.
6. Felds S. Introduction. Endocr Pract. 2002;8:40-82.
7. Monnier L, Lapinski H, Collette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyper glycemia of type 2 diabetic patients: variations with increasing levels of HBA(1c). Diabetes Care. 2003;26:881-885.
8. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ. 2006;32(suppl):9S-18S.
9. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;29:977-986.
10. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
11. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
12. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
13. Stout RW. Insulin and atheromas: 20-yr perspective. Diabetes Care. 1990;13:631-654.
14. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
15. The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. JAMA. 2003;290:2159-2167.
16. Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm. 2003;9:309-316.
17. Schwartz S, Sievers R, Strange P, et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care. 2003;26:2238-2243.
18. Bolli GB, Gerich JE. The "dawn phenomenon": a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984;310:746-750.
19. Heise T, Tusek C, Bott S, et al. Investigating the drug accumulation of two premixed insulins. Diabetes. 2003;52:A121.
20. LePore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
21. Raskin P, Bode BW, Marck JH, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group. 24-week study Diabetes Care. 2003;26:2598-2603.
22. Wainstein J, Metzger M, Boaz M, et al. Insulin pump therapy vs multiple daily injections in obese type 2 diabetic patients. Diabet Med. 2005;22:1037-1046.
23. Herman WH, Hag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568-1573.
24. Knee TS, Seidensicker DF, Walton JL, et al. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series, Endocr Pract. 2003;9:181-186.
25. Gross TM, Kayne D, King A, et al. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther. 2003;5:365-369.
26. Bain SC, Gill GV. Characteristics of type 1 diabetes of over 50 years duration (the Golden Years Cohort). Diabet Med. 2003;20:808-811.
27. US Department of Health and Human Services. Medicare National Coverage Determinations [Publication 100-03]. Washington. DC: Centers for Medicare & Medicaid Services Manual System: 2005.